Overview

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Gateway for Cancer Research
Treatments:
Ipilimumab
Nivolumab